Talecris Biotherapeutics (TLCR) plans to go public this week. The biotech company is a maker of plasma-derived protein therapies, formerly for Bayer. According to FierceBiotech, the company had originally planned to go public back in 2007, before the market meltdown pushed share prices down. But Talecris, based in Research Triangle Park, put that plan aside when it inked a deal to merge with an...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Talecris Biotherapeutics HOT Biotechnology Stock
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account